Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
In today’s episode, we look at MindMed’s (Nasdaq: MNMD, NEO: MMED) Project Flow, which is their LSD microdosing division. At present, MindMed’s microdosing program is split into 2 projects: base testing of LSD microdoses in healthy individuals, and using LSD microdoses to treat adult ADHD.
We will explore the progress made on both fronts, and where the program will expand to in the future, such as psilocybin (magic mushrooms) microdosing.
Ultimately, MindMed wants to answer questions such as:
Can microdosing psychedelics treat ADHD?
Can microdosing LSD improve your concentration?
Can microdosing decrease your anxiety?
Does microdosing increase creativity?
Does microdosing improve your mood?
Recently MindMed announced they are ready to begin recruiting for a study testing the variations in effect when taking LSD microdoses in the morning, compared to at night. The study will also try to answer the last four above questions. We discuss this study extensively.
Links:
MindMed Project Flow: https://mindmed.co/psychedelic-inspired/#scroll_section-2
MindMed New study: https://psilocybinalpha.com/news/mindmed-launches-study-of-low-dose-lsd-effects-on-sleep-and-cognitive-measures
Imperial College of London study: https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds
Project Albert Quote: https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/
Kim Kuypers Study: https://www.nature.com/articles/s41598-021-01811-4
MindMed Investor’s Deck: https://mindmed.co/wp-content/uploads/2021/11/MindMed-Presentation-11.17-compressed.pdf
LSD for ADHD: https://mindmed.co/news/press-release/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator/
https://mindmed.co/news/press-release/mindmeds-microdosing-division-further-expands-phase-2-clinical-trial-of-microdosing-lsdfor-adult-adhd/
Previous MindMed LSD study: https://mindmed.co/news/press-release/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd/
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Mindmed #MNMDstock #Microdosing
LOTS of news happened this week, one of the major ones being Red Light Holland’s merger with a CANNABIS Company called Cresco. Other news we discuss in today’s segment is atai Life Sciences Nasdaq uplisting, MindMed’s new addition to the team, Numinus’ Uplisting and Field Trip’s upcoming financial results.
Enjoy!
Timestamps:
0:00 – Intro
1:00 – atai Life Sciences Nasdaq IPO
2:56 -Red Light Holland Merging With A Cannabis Company & Acquisition
7:26 -Numinus Wellness Uplists To The TSX
8:45 – MindMed Appoints Peter Bergethon To Their Scientific Advisory Board
10:36 – Field Trip’s Upcoming Financial Results
Links:
atai Life Sciences ( NASDAQ: atai)
https://www.cnbc.com/2021/06/18/peter-thiel-backed-psychedelic-start-ups-shares-pop-in-wall-street-debut.html
Red Light Holland ( CSE: TRIP / OTC: TRUFF) Closes Acquisition of 80% of Happy Caps Mushroom Farm:
https://ca.finance.yahoo.com/news/red-light-holland-closes-acquisition-122000805.html
Red Light Holland is Merging with a Cannabis company called Creso Pharma to create The HighBrid Lab:
https://www.newsfilecorp.com/release/87740/Creso-Pharma-and-Red-Light-Holland-Merge-to-Introduce-The-HighBrid-Lab-TM-a-Leading-Global-Psychedelics-x-Cannabis-Company-Specializing-in-Recreational-Products-Applied-Science-Technology-and-Innovation
Numinus Wellness (OTC: LKYSF, TSX.V: NUMI) Uplists to Tier 1 on the TSX Venture Exchange:
https://thecannabisstock.com/2021/06/18/numinus-wellness-gradu
MindMed (NASDAQ: MNMD, NEO: MMED) Appoints Pharmaceutical Veteran, DR Peter Bergethon to their Scientific Advisory Board:
https://www.prnewswire.com/news-releases/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-md-to-scientific-advisory-board-301314501.html
Field Trip Health (OTC: FTRPF, TSX: FTRP) Will Release Financial Results for its fiscal fourth quarter and full year 2021 ended March 31, 2021:
https://ca.movies.yahoo.com/field-trip-health-ltd-announces-131000469.html
https://www.meetfieldtrip.com/news/news-details/2021/Field-Trip-Health-Ltd.-Schedules-Fiscal-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Conference-Call-for-Friday-June-25-2021-At-800-am-ET/default.aspx
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
editing:@themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#RedLightHolland #MindMed #atai
Mr. Psychedelic Law’s Co-Founding Partner, Dustin Robinson, talks about how he became involved with the medicinal psychedelic space.
In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.
In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?
The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?
Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.
Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.
It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.
James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.
In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Cybin #Psilocybin #Psychedelics
In this Psychedelic Spotlight exclusive, we speak with California Senator,…
In this episode, we get into what to expect at a Psychedelic Retreat that offers Co-Therapy, and some serious transformational energy. Listen to Andrew from Sayulita Wellness Retreat speak about his life-changing revelation, and the reasons why folks come to Psychedelic Retreats.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
